Andreas Reiff, MD, is the current Chief Medical Officer of Neutrolis a precision medicine platform company that directly targets Neutrophil Extracellular Traps (NETs) in Autoimmunity and other conditions. In his current role he oversees the clinical development and medical strategy and is responsible for guiding the company through clinical trials, regulatory submissions, and medical affairs, dedicated to bringing a transformative pipeline of anti Netosis drug candidates to market.
Prior to his current role he served as the Senior Vice President and global therapeutic area head for Inflammation/Immunology at Parexel International Global Medical Services, a global Contract Research Organization (CRO) based in Boston, MA, where he led a team of 32 subject matter experts and oversaw drug development in the areas of rheumatology, allergy, dermatology, gastroenterology and ophthalmology.
Before joining Parexel, Dr Reiff was the Chief Medical Officer at TheraKine Inc., specializing in innovative biodegradable polymer technology for drug delivery within the eye.
He is an Emeritus Professor of Pediatrics at the Keck School of Medicine of the University of Southern California, and the former Division Head of the Division of Rheumatology at Children’s Hospital Los Angeles. He was also the director of the Pediatric Rheumatology Program at Miller Children’s Hospital in Long Beach, CA, and a Visiting Clinical Associate Professor at the University of Nevada School of Medicine’s Department of Pediatrics. He currently also holds an academic appointment as Adjunct Professor of Rheumatology at the Oregon Health Science University,
Dr Reiff’s career began with a medical degree from the University Medical School in Freiburg, Germany, followed by various residencies and fellowships focused on internal medicine, bone marrow transplantation and pediatric rheumatology. He has led numerous clinical trials, acted as a consultant for several pharmaceutical companies, and shared his expertise through publications, book chapters and lectures worldwide on rheumatology and biologic drug development.
A member of various rheumatology societies and advisory boards, Dr Reiff is recognized internationally for his contributions to the field of pediatric rheumatology and the treatment of chronic inflammatory eye diseases. He is board-certified in pediatrics and pediatric rheumatology and has been honored with several awards for his work in the field.